UCSF

ZINC00537928

Substance Information

In ZINC since Heavy atoms Benign functionality
July 24th, 2004 34 Yes

Other Names:

1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-.alpha.,.alpha.-diphenyl-

1-piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-a,a-diphenyl-, monohydrochloride

1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-

1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-, hydrochloride; 1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-, monohydrochloride; 1-Piperidinebutanamide, 4-(4-chlorophenyl)-

2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

34552-83-5 (mono-hydrochloride)

34552-83-5; D00729; Imodium (TN); Loperamide hydrochloride (JAN/USP)

34552-83-5; Loperamide hydrochloride; Prestwick_302

4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide

4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide

4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide

4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide

4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride

5-21-02-00379 (Beilstein Handbook Reference)

53179-11-6

53179-11-6; C07080; Loperamide

53179-11-6; D08144; Diamide (TN); Loperamide (INN)

AB00053697

AC1L1H38

AKOS000573892

Apo-Loperamide

Apo-Loperamide;Imodium A-D;Imodium A-D Caplets;Kaopectate II;Loperacap;Loperamide hydrochloride;Maalox Anti-Diarrheal;Nu-Loperamide;PMS-Loperamide;Rho-Loperamide

BAS 01889668

Bio1_000082

Bio1_000571

Bio1_001060

Bio2_000101

Bio2_000581

BPBio1_000274

BRD-K61250553-001-02-9

BRD-K61250553-003-05-8

BRN 1558273

BSPBio_000248

BSPBio_001381

BSPBio_002769

C07080

C29H33ClN2O2

C29H33ClN2O2.C8H24O2Si3.Cl; IMODIUM ADVANCED; LOPERAMIDE HYDROCHLORIDE; SIMETHICONE; LS-178564

CAS-34552-83-5

CBiol_001796

CHEBI:162259

CHEBI:6532

CHEMBL841

CID3955

CPD000058466; Imodium; SAM002564218

CPD000058466; Loperamide hydrochloride; SAM002564218

D08144

DAP000425

DB00836

Diamide (TN)

Diarr-Eze

DivK1c_000215

EINECS 258-416-5

FDA)

HMS1791F03

HMS1989F03

HMS2089C13

IDI1_000215

IDI1_033851

Imodium

Imodium a-d

Imodium A-D Caplets

Imodium a-d ez chews

Imodium advanced

INN)

INN); Loperamide HCl (FDA

INN); Loperamide HCl (JAN

Ioperamide

JAN

Kaopectate II

KBio1_000215

KBio2_000101

KBio2_000854

KBio2_002669

KBio2_003422

KBio2_005237

KBio2_005990

KBio3_000201

KBio3_000202

KBio3_001989

KBioGR_000101

KBioGR_001685

KBioSS_000101

KBioSS_000854

L000709

Loperacap

Loperamida

Loperamida [INN-Spanish]

loperamida; loperamide; loperamidum

Loperamide

Loperamide (BAN

Loperamide (hydrochloride)

Loperamide (INN)

Loperamide HCL

Loperamide Hydrochloride (FDA

Loperamide Monohydrochloride

Loperamide [INN:BAN]

Loperamide, HCl

loperamidehydrochloride

Loperamidum

Loperamidum [INN-Latin]

LS-114352

Maalox Anti-Diarrheal

MFCD00058581

MFCD00600388

MolPort-001-969-016

N/A

NCGC00015608-01

NCGC00015608-08

NCGC00016828-01

NCGC00024818-01

NCGC00024818-02

NCGC00024818-03

NCGC00024818-04

NCGC00024818-05

nchembio.559-comp8

nchembio.79-comp7

NINDS_000215

Nu-Loperamide

Oprea1_109220

Pepto Diarrhea Control

PMS-Loperamide

Prestwick0_000144

Prestwick1_000144

Prestwick2_000144

Prestwick3_000144

R-18553

Rho-Loperamide

SPBio_001816

SPBio_002187

Spectrum2_001738

Spectrum3_001015

Spectrum4_001143

Spectrum5_001374

Spectrum_000374

ST095179

Tocris-0840

UNII-6X9OC3H4II

USAN

USP

USP)

USP); Loperamide (BAN

Download: MOL2 SDF SMILES Flexibase

Annotations

Vendors

Physical Representations

Type pH range xlogP Des A‑Pol Apolar desolvation (kcal/mol) Des Pol Polar desolvation (kcal/mol) H Don H-bond donors H Acc H-bond acceptors Chg Net charge tPSA (Ų) MWT Molecular weight (g/mol) RB Rotatable bonds DL
Ref Reference (pH 7) 4.88 12.85 -54.69 2 4 1 45 478.056 7

Vendor Notes

Note Type Comments Provided By
MP 223 TCI
ALOGPS_SOLUBILITY 8.60e-04 g/l DrugBank-approved
purity 9.500000000000000e+001 Enamine Building Blocks Enamine Building Blocks
therap Ca channel blocker MicroSource Spectrum
Therapy Meperidine congener which binds to opioid receptors; Ca2+ channel antagonist SMDC Iconix
PUBCHEM_SUBSTANCE_COMMENT NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : L-5907; NCC_SUPPLIER_SAMPLE_COMMENTS : WHITE POWDER; 1 hydrogen chloride NIH Clinical Collection via PubChem
Target Opioid Receptor Selleck Chemicals
Reactome Database Links REACT_13765 ChEBI
PUBCHEM_SUBSTANCE_COMMENT SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: L-5907; SALT: 1 hydrogen chloride; SUPPLIER_COMMENTS: WHITE POWDER NIH Clinical Collection via PubChem

Activity (Go SEA)

Clustered Target Annotations
Code Description Organism Class Affinity (nM) LE (kcal/mol/atom) Type
OPRD-1-E Delta Opioid Receptor (cluster #1 Of 3), Eukaryotic Eukaryotes 50 0.30 Binding ≤ 10μM
OPRM-1-E Mu-type Opioid Receptor (cluster #1 Of 4), Eukaryotic Eukaryotes 1 0.37 Binding ≤ 10μM
SCN1A-2-E Sodium Channel Protein Type I Alpha Subunit (cluster #2 Of 2), Eukaryotic Eukaryotes 270 0.27 Binding ≤ 10μM
SCN2A-1-E Sodium Channel Protein Type II Alpha Subunit (cluster #1 Of 2), Eukaryotic Eukaryotes 270 0.27 Binding ≤ 10μM
SCN3A-2-E Sodium Channel Protein Type III Alpha Subunit (cluster #2 Of 2), Eukaryotic Eukaryotes 270 0.27 Binding ≤ 10μM
SCN8A-2-E Sodium Channel Protein Type VIII Alpha Subunit (cluster #2 Of 2), Eukaryotic Eukaryotes 270 0.27 Binding ≤ 10μM
OPRD-1-E Delta Opioid Receptor (cluster #1 Of 1), Eukaryotic Eukaryotes 156 0.28 Functional ≤ 10μM
OPRM-1-E Mu Opioid Receptor (cluster #1 Of 2), Eukaryotic Eukaryotes 58 0.30 Functional ≤ 10μM
Z50466-1-O Trypanosoma Cruzi (cluster #1 Of 8), Other Other 3000 0.23 Functional ≤ 10μM
Z50512-1-O Cavia Porcellus (cluster #1 Of 7), Other Other 489 0.26 Functional ≤ 10μM
ChEMBL Target Annotations
Uniprot Swissprot Description Affinity (nM) LE (kcal/mol/atom) Type
OPRD_RAT P33533 Delta Opioid Receptor, Rat 50.1 0.30 Binding ≤ 1μM
OPRM_RAT P33535 Mu Opioid Receptor, Rat 0.16 0.40 Binding ≤ 1μM
OPRM_HUMAN P35372 Mu Opioid Receptor, Human 0.53 0.38 Binding ≤ 1μM
SCN1A_HUMAN P35498 Sodium Channel Protein Type I Alpha Subunit, Human 270 0.27 Binding ≤ 1μM
SCN2A_HUMAN Q99250 Sodium Channel Protein Type II Alpha Subunit, Human 270 0.27 Binding ≤ 1μM
SCN3A_HUMAN Q9NY46 Sodium Channel Protein Type III Alpha Subunit, Human 270 0.27 Binding ≤ 1μM
SCN8A_HUMAN Q9UQD0 Sodium Channel Protein Type VIII Alpha Subunit, Human 270 0.27 Binding ≤ 1μM
OPRD_RAT P33533 Delta Opioid Receptor, Rat 50.1 0.30 Binding ≤ 10μM
OPRM_HUMAN P35372 Mu Opioid Receptor, Human 0.53 0.38 Binding ≤ 10μM
OPRM_RAT P33535 Mu Opioid Receptor, Rat 0.16 0.40 Binding ≤ 10μM
SCN1A_HUMAN P35498 Sodium Channel Protein Type I Alpha Subunit, Human 270 0.27 Binding ≤ 10μM
SCN2A_HUMAN Q99250 Sodium Channel Protein Type II Alpha Subunit, Human 270 0.27 Binding ≤ 10μM
SCN3A_HUMAN Q9NY46 Sodium Channel Protein Type III Alpha Subunit, Human 270 0.27 Binding ≤ 10μM
SCN8A_HUMAN Q9UQD0 Sodium Channel Protein Type VIII Alpha Subunit, Human 270 0.27 Binding ≤ 10μM
Z50512 Z50512 Cavia Porcellus 488.9 0.26 Functional ≤ 10μM
OPRD_HUMAN P41143 Delta Opioid Receptor, Human 156 0.28 Functional ≤ 10μM
OPRM_HUMAN P35372 Mu Opioid Receptor, Human 58 0.30 Functional ≤ 10μM
Z50466 Z50466 Trypanosoma Cruzi 3000 0.23 Functional ≤ 10μM

Direct Reactome Annotations (via ChEBI)

Description Species
Xenobiotics

Reactome Annotations from Targets (via Uniprot)

Description Species
G alpha (i) signalling events
G-protein activation
Interaction between L1 and Ankyrins
Opioid Signalling
Peptide ligand-binding receptors

Analogs ( Draw Identity 99% 90% 80% 70% )